scholarly journals Ocular adnexal non-Hodgkin’s lymphoma: a review of epidemiology and risk factors

2011 ◽  
Vol 6 (2) ◽  
pp. 181-193 ◽  
Author(s):  
Roxana Moslehi ◽  
Maria J Schymura ◽  
Seema Nayak ◽  
F Bruce Coles
Keyword(s):  
Risk Factors ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Agricultural risk factors for t(14;18) subtypes of non-Hodgkin’s lymphoma

Epidemiology ◽  
2001 ◽  
Vol 12 (6) ◽  
pp. 701-709 ◽  
Author(s):  
Jane C. Schroeder ◽  
Andrew F. Olshan ◽  
Ralph Baric ◽  
Georgette A. Dent ◽  
Clarice R. Weinberg ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Agricultural Risk ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Re: Medical History Risk Factors for Non-Hodgkin's Lymphoma in Older Women

1997 ◽  
Vol 89 (11) ◽  
pp. 816-817 ◽  
Author(s):  
E. Weiderpass ◽  
O. Nyren ◽  
A. Ekbom ◽  
H.-O. Adami ◽  
G. Gridley ◽  
...  
Keyword(s):  
Risk Factors ◽  
Medical History ◽  
Older Women ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Risk Factors for Venous Thromboembolism (VTE) among Patients with Active Hematological Cancer: A Population-Based Case-Control Study.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1642-1642
Author(s):  
Aneel A. Ashrani ◽  
John A. Heit ◽  
Jeffrey A. Schmoll ◽  
Sara A. Farmer ◽  
Tanya M. Petterson ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Leukemia ◽  
Cancer Patients ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Cancer Type ◽  
Hematological Cancer ◽  
Stage Progression ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Background: Hematological cancer patients are at an increased risk for VTE (RR range = 12–32). However, whether VTE risk among such patients can be further stratified is uncertain. Objective: To test hematological cancer type, stage, stage progression and chemotherapy as potential risk factors for VTE among active hematological cancer patients after controlling for other previously-identified VTE risk factors. Methods: Using the resources of the Rochester Epidemiology Project, Mayo Clinic Master Diagnostic Index and Mayo Clinic Tumor Registry, we identified all Olmsted County, MN residents with active hematological cancer over the 28-year period, 1973–2000. From this prevalence cohort, we identified 86 patients with no prior VTE (controls) who were matched on age and date of hematological cancer diagnosis to 86 hematological cancer patients with incident VTE over the same time frame (cases). For all cases and controls, we reviewed the complete medical records in the community for baseline and hematological cancer-related characteristics. Hematological cancers were re-staged at the dates of the cancer and VTE diagnosis. We tested these characteristics as potential risk factors for VTE in active hematological cancer using conditional logistic regression. Results: In an initial multivariate analysis that included body mass index (BMI), hospitalization, and any infection or central venous catheter placement within 90 days prior to the VTE event, VTE was significantly associated with hospitalization (OR=6.70; p<0.001), and marginally associated with any infection (OR=2.18; p=0.09). After adjusting for the above variables, chemotherapy administered within the preceding 90 days was significantly associated with VTE (OR=4.25; p=0.02), while stage progression was marginally associated (OR=4.79; p=0.10). Compared to all other hematological cancer types, acute leukemia (OR=5.95; p=0.01) and non-Hodgkin’s lymphoma (OR=2.61; p=0.01) were associated with VTE. However, after adjusting for BMI, hospitalization, any infection and central venous catheter, only non-Hodgkin’s lymphoma was independently associated with VTE (OR=3.79, p=0.009), while acute leukemia was not (OR=2.66, p=0.35). Conclusions: Hematological cancer type (in particular, non-Hodgkin’s lymphoma and possibly acute leukemia), recent hospitalization, recent chemotherapy, and possibly stage progression and recent infection, are risk factors for VTE among patients with active hematological cancer.

Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma

2008 ◽  
Vol 26 (19) ◽  
pp. 3159-3165 ◽  
Author(s):  
Dawn L. Hershman ◽  
Russell B. McBride ◽  
Andrew Eisenberger ◽  
Wei Yann Tsai ◽  
Victor R. Grann ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Disease ◽  
Elderly Patients ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cardiac Risk ◽  
Hodgkin's Lymphoma ◽  
Cardiac Risk Factors ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Purpose Anthracycline-based chemotherapy, which improves survival for patients with non-Hodgkin's lymphoma, is often withheld from elderly patients because of its cardiotoxicity. We studied the cardiac effects of doxorubicin in a population-based sample of older patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods Among patients age ≥ 65 years diagnosed with DLBCL from 1991 to 2002 in the Surveillance, Epidemiology, and End Results–Medicare database, we developed logistic regression models of the associations of doxorubicin with demographic, clinical, and cardiac variables. We then developed Cox proportional hazards models of the association between doxorubicin and subsequent congestive heart failure (CHF), taking predictors of CHF into account. Results Of 9,438 patients with DLBCL, 3,164 (42%) received doxorubicin-based chemotherapy. Any doxorubicin use was associated with a 29% increase in risk of CHF (95% CI, 1.02 to 1.62); CHF risk increased with number of doxorubicin claims, increasing age, prior heart disease, comorbidities, diabetes, and hypertension; hypertension intensified the effect of doxorubicin on risk of CHF (hazard ratio = 1.8; P < .01). In the 8 years after diagnosis, the adjusted CHF-free survival rate was 74% in doxorubicin-treated patients versus 79% in patients not treated with doxorubicin. Conclusion Among patients receiving chemotherapy for DLBCL, those with prior heart disease were less likely than others to be treated with doxorubicin, and those who received doxorubicin were more likely than others to develop CHF. Various cardiac risk factors increased CHF risk, but only hypertension was synergistic with doxorubicin. Doxorubicin has dramatically improved survival of DLBCL patients; nonetheless, some subgroups may benefit from efforts to reduce doxorubicin-related CHF risk.

scholarly journals Medical History Risk Factors for Non-Hodgkin's Lymphoma in Older Women

1997 ◽  
Vol 89 (4) ◽  
pp. 314-318 ◽  
Author(s):  
J. R. Cerhan ◽  
R. B. Wallace ◽  
C. T. Lutz ◽  
A. R. Folsom ◽  
S. Thomas A. ◽  
...  
Keyword(s):  
Risk Factors ◽  
Medical History ◽  
Older Women ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study

2004 ◽  
Vol 22 (21) ◽  
pp. 4302-4311 ◽  
Author(s):  
Gary H. Lyman ◽  
David C. Dale ◽  
Jonathan Friedberg ◽  
Jeffrey Crawford ◽  
Richard I. Fisher
Keyword(s):  
Risk Factors ◽  
Hodgkin’S Lymphoma ◽  
Performance Status ◽  
Significant Risk ◽  
Dose Intensity ◽  
Hodgkin's Lymphoma ◽  
Disease Stage ◽  
Poor Performance Status ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Purpose To assess the incidence of and risk factors for reduced relative dose-intensity (RDI) in patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). Methods A nationwide survey was conducted of 567 oncology practices with data extracted from the records of 4,522 patients with aggressive NHL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP); CHOP-rituximab (CHOP-R); or cyclophosphamide, mitoxantrone, vincristine, and prednisone (CNOP). The primary outcome was the average RDI for each regimen based on both planned and reference standards. Other assessments included the incidence of febrile neutropenia and patterns of colony-stimulating factor (CSF) use, as well as the average RDI in high-risk subgroups. Results Dose reductions ≥ 15% occurred in 40% of patients and treatment delays ≥ 7 days occurred in 24% of patients, resulting in 53% and 48% of patients receiving an RDI less than 85% of the minimum six-cycle and National Comprehensive Cancer Network guideline standards, respectively. Reduced RDI was more prevalent in older patients, with 60% of patients older than 60 years receiving RDI less than 85%. Multivariate analysis identified several independent predictors for reduced RDI, including age older than 60 years, advanced disease stage, poor performance status, and no prophylactic CSF use. Age was no longer a significant risk factor in patients who received prophylactic CSF. Conclusion Patients with aggressive and potentially curable NHL treated with CHOP, CHOP-R, or CNOP frequently receive reduced RDI. Predictive models based on the risk factors identified for reduced RDI should enable the targeted use of appropriate supportive care, facilitating the delivery of full chemotherapy doses on schedule.

Sign in / Sign up

Export Citation Format

Share Document